289 related articles for article (PubMed ID: 32701720)
21. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
22.
Chaloupka M; Herlemann A; D'Anastasi M; Cyran CC; Ilhan H; Gratzke C; Stief CG
Urol Clin North Am; 2017 Nov; 44(4):557-563. PubMed ID: 29107272
[TBL] [Abstract][Full Text] [Related]
23. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence.
Ferdinandus J; Fendler WP; Hadaschik B; Herrmann K
Curr Opin Urol; 2020 Sep; 30(5):635-640. PubMed ID: 32732621
[TBL] [Abstract][Full Text] [Related]
25. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
26. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
27. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
28. A Prospective Comparison of
Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
Mottaghy FM; Heinzel A; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1397-9. PubMed ID: 27118189
[No Abstract] [Full Text] [Related]
30. Impact of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography on the Therapeutic Decision of Prostate Carcinoma Primary Staging: A Retrospective Analysis at the Brazilian National Public Health System.
da Silva ACB; de Toledo LGM; de Carvalho Fernandes R; Ziroldo AR; Sawczyn GV; Alarcon ST; Lewin F
Ann Surg Oncol; 2023 Jul; 30(7):4541-4549. PubMed ID: 36995451
[TBL] [Abstract][Full Text] [Related]
31. Prostate specific membrane antigen positron emission tomography/computed tomography and staging high risk prostate cancer: a non-systematic review of high clinical impact literature.
Morigi JJ; Anderson J; DE Nunzio C; Fanti S
Minerva Urol Nephrol; 2021 Feb; 73(1):32-41. PubMed ID: 32550630
[TBL] [Abstract][Full Text] [Related]
32. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
33. The accuracy and intra- and interobserver variability of PSMA PET/CT for the local staging of primary prostate cancer.
Donswijk ML; Ettema RH; Meijer D; Wondergem M; Cheung Z; Bekers EM; van Leeuwen PJ; van den Bergh RCN; van der Poel HG; Vis AN; Oprea-Lager DE
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1741-1752. PubMed ID: 38273003
[TBL] [Abstract][Full Text] [Related]
34. Gallium-68 Prostate-Specific Membrane Antigen PET Imaging.
Hofman MS; Iravani A
PET Clin; 2017 Apr; 12(2):219-234. PubMed ID: 28267455
[TBL] [Abstract][Full Text] [Related]
35. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
Haran C; McBean R; Parsons R; Wong D
J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic Accuracy of
Cantiello F; Gangemi V; Cascini GL; Calabria F; Moschini M; Ferro M; Musi G; Butticè S; Salonia A; Briganti A; Damiano R
Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
[TBL] [Abstract][Full Text] [Related]
37.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
39. Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence-A Narrative Review of the Literature.
Ekmekcioglu Ö; Busstra M; Klass ND; Verzijlbergen F
J Nucl Med; 2019 Oct; 60(10):1394-1398. PubMed ID: 30850500
[No Abstract] [Full Text] [Related]
40. Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria.
Fanti S; Hadaschik B; Herrmann K
J Nucl Med; 2020 May; 61(5):678-682. PubMed ID: 31806774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
